Lilly Announces Changes in Senior Leadership
Mike Harrington, senior vice president and general counsel, will retire at the end of the year. Christi Shaw, senior vice president and president Lilly Bio-Medicines, has announced she will leave Lilly at the end of August. Patrik Jonsson, currently president and general manager of Lilly Japan, will succeed Shaw.
Harrington has been a member of Lilly's executive committee for seven years—a period of strong growth and change for the company.
"Thanks to Mike's leadership, the company maintained patent exclusivity for a number of important medicines, including Alimta®, completed the Elanco divestiture and finalized acquisitions such as Loxo Oncology and ARMO BioSciences," said
A search is underway for Harrington's successor.
Ricks also commented on the company's other leadership changes.
"During Christi's tenure, our Bio-Medicines division launched multiple new medicines globally, such as Olumiant ® and Emgality ®, and added key development projects to our early and late phase portfolio," said Ricks. "I value the external perspective and passion for patients that Christi brought to the company."
Jonsson will be promoted to senior vice president and president of Lilly Bio-Medicines pending completion of work authorization in the U.S.
"Patrik is a patient-focused, inclusive leader who has a long track record of delivering results in numerous markets around the world," said Ricks. "With a portfolio of newly launched medicines and a robust pipeline in both immunology and pain, he is the right person to lead our Bio-Medicines business."
Additional details about Harrington, Shaw and Jonsson
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. C-LLY
This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs. There are risks and uncertainties related to leadership changes, including with regard to identifying a successor to Mr. Harrington and the timing of these changes. For discussion of important risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the
Kelley Murphy; email@example.com; 317-701-4007 (Media)
Kevin Hern; firstname.lastname@example.org; (317) 277-1838 (Investors)
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-announces-changes-in-senior-leadership-300883173.html